Patient Characteristics
| . | No Prior CHT . | Prior CHT . | Total . |
|---|---|---|---|
| Total no. | 21 | 8 | 29 |
| Male/female | 16/5 | 6/2 | 22/7 |
| Median age in years (range) | 32 | 36 | 34 |
| (23-48) | (28-49) | (23-49) | |
| Risk group | |||
| Intravenous drug user | 13 | 2 | 15 |
| Homosexual | 4 | 3 | 7 |
| Heterosexual | 4 | 3 | 7 |
| Prior AIDS | |||
| Opportunistic infections | 9 | 2 | 11 |
| Kaposi sarcoma | 0 | 2 | 2 |
| Prior antiretroviral therapy | |||
| AZT (dose/duration) | 7 | 4 | 11 |
| (500 mg/22 mo) | (500 mg/20 mo) | (500 mg/21.5 mo) | |
| DDI (dose/duration) | 3 | 2 | 5 |
| (200 mg/19 mo) | (200 mg/15 mo) | (200 mg/16 mo) | |
| CD4 mean | 164 ± 182 | 49.9 ± 52 | 132.7 ± 164 |
| CD4 median (range) | 164 | 48.7 | 132.7 |
| (4.7-605) | (4.3-167) | (4.3-605) | |
| CD4 <100/μL | 12 | 7 | 19 |
| LDH | |||
| Normal | 8 | 5 | 13 |
| > Normal | 13 | 3 | 16 |
| Performance status | |||
| 0-1 | 8 | 4 | 12 |
| 2-3 | 13 | 4 | 17 |
| Stage | |||
| I | 2 | 0 | 2 |
| II | 4 | 1 | 5 |
| III | 0 | 0 | 0 |
| IV | 15 | 7 | 22 |
| Histology | |||
| Burkitt | 6 | 2 | 8 |
| DLBCL | 9 | 4 | 13 |
| Lymphoblastic | 0 | 1 | 1 |
| PTCL | 3 | 0 | 3 |
| ALC | 1 | 1 | 2 |
| Unclassified | 2 | 0 | 2 |
| Extranodal disease | 19 | 7 | 26 |
| Bulky disease (>10 cm) | 9 | 4 | 13 |
| Previous treatment | |||
| F-MACHOP | 1 | 1 | |
| αIFN | 1 | 1 | |
| CVP | 3 | 3 | |
| ABVD | 1 | 1 | |
| CHOP | 1 | 1 | |
| VCR + P | 1 | 1 |
| . | No Prior CHT . | Prior CHT . | Total . |
|---|---|---|---|
| Total no. | 21 | 8 | 29 |
| Male/female | 16/5 | 6/2 | 22/7 |
| Median age in years (range) | 32 | 36 | 34 |
| (23-48) | (28-49) | (23-49) | |
| Risk group | |||
| Intravenous drug user | 13 | 2 | 15 |
| Homosexual | 4 | 3 | 7 |
| Heterosexual | 4 | 3 | 7 |
| Prior AIDS | |||
| Opportunistic infections | 9 | 2 | 11 |
| Kaposi sarcoma | 0 | 2 | 2 |
| Prior antiretroviral therapy | |||
| AZT (dose/duration) | 7 | 4 | 11 |
| (500 mg/22 mo) | (500 mg/20 mo) | (500 mg/21.5 mo) | |
| DDI (dose/duration) | 3 | 2 | 5 |
| (200 mg/19 mo) | (200 mg/15 mo) | (200 mg/16 mo) | |
| CD4 mean | 164 ± 182 | 49.9 ± 52 | 132.7 ± 164 |
| CD4 median (range) | 164 | 48.7 | 132.7 |
| (4.7-605) | (4.3-167) | (4.3-605) | |
| CD4 <100/μL | 12 | 7 | 19 |
| LDH | |||
| Normal | 8 | 5 | 13 |
| > Normal | 13 | 3 | 16 |
| Performance status | |||
| 0-1 | 8 | 4 | 12 |
| 2-3 | 13 | 4 | 17 |
| Stage | |||
| I | 2 | 0 | 2 |
| II | 4 | 1 | 5 |
| III | 0 | 0 | 0 |
| IV | 15 | 7 | 22 |
| Histology | |||
| Burkitt | 6 | 2 | 8 |
| DLBCL | 9 | 4 | 13 |
| Lymphoblastic | 0 | 1 | 1 |
| PTCL | 3 | 0 | 3 |
| ALC | 1 | 1 | 2 |
| Unclassified | 2 | 0 | 2 |
| Extranodal disease | 19 | 7 | 26 |
| Bulky disease (>10 cm) | 9 | 4 | 13 |
| Previous treatment | |||
| F-MACHOP | 1 | 1 | |
| αIFN | 1 | 1 | |
| CVP | 3 | 3 | |
| ABVD | 1 | 1 | |
| CHOP | 1 | 1 | |
| VCR + P | 1 | 1 |
Abbreviations: PTCL, peripheral T-cell lymphoma; ALC, anaplastic large-cell lymphoma; CHT, chemotherapy.